NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: NEULANDLAB · data 2026-10-30
Neuland Laboratories Ltd.
In plain words
Price: 18.7% below its 52-week high of ₹24,225.
Delivery: 49.4% of traded shares were kept for delivery over the last 10 sessions, against 46.8% over the last 60.
Latest results: a net profit of ₹148 cr for the quarter ended Jun 2026 (+962.4% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,372 cr |
| Net profit (last 12 months) | ₹498 cr |
| Sales growth, 3 years (yearly) | 19.3% |
| Profit growth, 3 years (yearly) | 30.6% |
Latest results in brief (Q1 FY27)
NEULANDLAB Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹641.58 crore, up 119.2% YoY and down 17.3% QoQ.
Net profit was ₹147.67 crore, up 962.4% YoY and down 30.6% QoQ.
Operating margin was 34.7% (11.8% a year ago).
EPS was ₹115.1, up 962.8% YoY and down 30.6% QoQ.
NEULANDLAB के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹641.58 करोड़; पिछले साल की तुलना में 119.2% की बढ़त, पिछली तिमाही की तुलना में 17.3% की गिरावट।
शुद्ध मुनाफ़ा: ₹147.67 करोड़; पिछले साल की तुलना में 962.4% की बढ़त, पिछली तिमाही की तुलना में 30.6% की गिरावट।
ऑपरेटिंग मार्जिन: 34.7% (एक साल पहले 11.8%)।
EPS: ₹115.1; पिछले साल की तुलना में 962.8% की बढ़त, पिछली तिमाही की तुलना में 30.6% की गिरावट।
NEULANDLABના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹641.58 કરોડ; ગયા વર્ષની સરખામણીએ 119.2% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 17.3% ઘટાડો.
ચોખ્ખો નફો: ₹147.67 કરોડ; ગયા વર્ષની સરખામણીએ 962.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 30.6% ઘટાડો.
ઓપરેટિંગ માર્જિન: 34.7% (એક વર્ષ પહેલાં 11.8%).
EPS: ₹115.1; ગયા વર્ષની સરખામણીએ 962.8% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 30.6% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
24/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 49.5% over the last 20 sessions vs 36.6% in the 40 before (1.35x); shares delivered per day 0.76x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 9/15: 10 schemes hold it, about ₹179 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 5 Aug 26Results Q1 FY27 results: profit +962.4% YoY +11.8% next session
- 24 Jul 26Dividend Dividend ₹34 (ex-date) +3.1% next session
- 12 May 26Results Q4 FY26 results: profit +664.7% YoY -6.0% next session
- 9 Feb 26Results Q3 FY26 results: profit −60.1% YoY +3.6% next session
- 7 Nov 25Results Q2 FY26 results: profit +194.9% YoY +3.2% next session
- 31 Jul 25Results Q1 FY26 results: profit −85.8% YoY -6.4% next session
- 18 Jul 25Dividend Dividend ₹12 (ex-date) -2.5% next session
- 16 May 25Results Q4 FY25 results: profit −58.8% YoY -5.4% next session
- 10 Feb 25Results Q3 FY25 results: profit +24.8% YoY -4.1% next session
- 6 Nov 24Results Q2 FY25 results: profit −63.2% YoY -13.1% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹642 cr | ₹148 cr | +962.4% | 34.7% | 115.1 |
| Mar 2026 | ₹776 cr | ₹213 cr | +664.7% | 39.6% | 165.76 |
| Dec 2025 | ₹440 cr | ₹41 cr | -60.1% | 17.5% | 31.62 |
| Sept 2025 | ₹514 cr | ₹97 cr | +194.9% | 30.2% | 75.49 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 32.26% | 32.62% | 32.63% | 32.63% |
| Foreign institutions (FII) | 21.93% | 21.08% | 20.46% | 20.90% |
| Domestic institutions (DII) | 16.26% | 16.51% | 15.84% | 14.71% |
| Mutual funds | 12.45% | 12.66% | 11.35% | 10.39% |
| Retail investors | 15.74% | 16.05% | 17.02% | 17.29% |
| Number of shareholders | 49,741 | 44,340 | 46,304 | 46,187 |
Common questions
What was Neuland Laboratories Ltd.'s latest quarterly profit?
Neuland Laboratories Ltd. reported a net profit of ₹148 cr for the quarter ended Jun 2026 (+962.4% on the same quarter a year earlier), on revenue of ₹642 cr.
How much do promoters hold in Neuland Laboratories Ltd.?
Promoters held 32.26% of Neuland Laboratories Ltd. at the end of Sept 2026, with 2.32% of promoter shares pledged.
Is Neuland Laboratories Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.16.
What is Neuland Laboratories Ltd.'s P/E ratio?
About 50.8, based on the last 12 months' earnings and a price of ₹19,700 (data 2026-10-30).
What is the 52-week high and low of Neuland Laboratories Ltd.?
The 52-week high is ₹24,225 and the 52-week low is ₹11,500.
Mutual funds holding Neuland Laboratories Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 10 schemes holding about ₹179 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Mirae Asset Small Cap Fund | Mirae Asset Mutual Fund | 1.78% | ₹104 cr |
| Nippon India Nifty Smallcap 250 Index Fund | Nippon India Mutual Fund | 0.82% | ₹28 cr |
| Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 2.06% | ₹19 cr |
| SBI Nifty Smallcap 250 Index Fund | SBI Mutual Fund | 0.82% | ₹14 cr |
| ADITYA BIRLA SUN LIFE NIFTY SMALLCAP 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 2.17% | ₹8 cr |
| Mirae Asset Nifty MidSmallcap400 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 0.82% | ₹4 cr |
| ADITYA BIRLA SUN LIFE BSE 500 MOMENTUM 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 0.90% | ₹1 cr |
| Mirae Asset Nifty Smallcap 250 ETF | Mirae Asset Mutual Fund | 0.82% | ₹1 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 1.36% | ₹0 cr |
| SBI Nifty Small Cap 250 ETF | SBI Mutual Fund | 0.83% | ₹0 cr |
Similar companies
Acutaas Chemicals Ltd (ACUTAAS) · Wockhardt Limited (WOCKPHARMA) · Piramal Pharma Limited (PPLPHARMA) · Cohance Lifesciences Ltd (COHANCE) · Shilpa Medicare Limited (SHILPAMED)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NEULANDLAB in NSE Scanner →